REFERENCES
- Coley W B. The treatment of malignant tumors by repeated inoculations of erysipelas: with a report of ten original cases. Am J Med Sci. 1893; 105: 487–511
- Burnet F M. The concept of immunological surveillance. Prog Exp Tumor Res. 1970; 13: 1–27, [PUBMED], [INFOTRIEVE]
- Boon T, Old L J. Cancer tumor antigens. Curr Opin Immunol. 1997; 9: 681–683, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Wang R F, Rosenberg S A. Human tumor antigens for cancer vaccine development. Immunol Rev. 1999; 170: 85–100, [PUBMED], [INFOTRIEVE], [CSA]
- Van Dooremaal J C. Die Entwicklung der in fremden Grund versetzten lebenden Geweba. Albrecht von Graefes Arch Ophthalmol. 1873; 19: 358–373
- Medawar P B. Immunity to homologous grafted skin. III. The fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye. Br J Exp Pathol. 1948; 29: 58–69
- Ma D, Luyten G P, Luider T M, Niederkorn J Y. Relationship between natural killer cell susceptibility and metastasis of human uveal melanoma cells in a murine model. Invest Ophthalmol Vis Sci. 1995; 36: 435–441, [PUBMED], [INFOTRIEVE], [CSA]
- Ma D, Niederkorn J Y. Transforming growth factor-beta down-regulates major histocompatibility complex class I antigen expression and increases the susceptibility of uveal melanoma cells to natural killer cell-mediated cytolysis. Immunology. 1995; 86: 263–269, [PUBMED], [INFOTRIEVE]
- Ljunggren H G, Ohlen C, Hoglund P, Franksson L, Karre K. The RMA-S lymphoma mutant; consequences of a peptide loading defect on immunological recognition and graft rejection. Int J Cancer Suppl. 1991; 6: 38–44, [PUBMED], [INFOTRIEVE]
- Apte R S, Mayhew E, Niederkorn J Y. Local inhibition of natural killer cell activity promotes the progressive growth of intraocular tumors. Invest Ophthalmol Vis Sci. 1997; 38: 1277–1282, [PUBMED], [INFOTRIEVE], [CSA]
- Apte R S, Niederkorn J Y. Isolation and characterization of a unique natural killer cell inhibitory factor present in the anterior chamber of the eye. J Immunol. 1996; 156: 2667–2673, [PUBMED], [INFOTRIEVE]
- Apte R S, Sinha D, Mayhew E, Wistow G J, Niederkorn J Y. Cutting edge: role of macrophage migration inhibitory factor in inhibiting NK cell activity and preserving immune privilege. J Immunol. 1998; 160: 5693–5696, [PUBMED], [INFOTRIEVE]
- Rook A H, Kehrl J H, Wakefield L M, Roberts A B, Sporn M B, Burlington D B, Lane H C, Fauci A S. Effects of transforming growth factor beta on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness. J Immunol. 1986; 136: 3916–3920, [PUBMED], [INFOTRIEVE]
- Lass J H, Walter E I, Burris T E, Grossniklaus H E, Roat M I, Skelnik D L, Needham L, Singer M, Medof M E. Expression of two molecular forms of the complement decay-accelerating factor in the eye and lacrimal gland. Invest Ophthalmol Vis Sci. 1990; 31: 1136–1148, [PUBMED], [INFOTRIEVE], [CSA]
- Sohn J H, Kaplan H J, Suk H J, Bora P S, Bora N S. Chronic low level complement activation within the eye is controlled by intraocular complement regulatory proteins. Invest Ophthalmol Vis Sci. 2000; 41: 3492–3502, [PUBMED], [INFOTRIEVE], [CSA]
- Sohn J H, Kaplan H J, Suk H J, Bora P S, Bora N S. Complement regulatory activity of normal human intraocular fluid is mediated by MCP, DAF, and CD59. Invest Ophthalmol Vis Sci. 2000; 41: 4195–4202, [PUBMED], [INFOTRIEVE], [CSA]
- Goslings W R, Prodeus A P, Streilein J W, Carroll M C, Jager M J, Taylor A W. A small molecular weight factor in aqueous humor acts on C1q to prevent antibody-dependent complement activation. Invest Ophthalmol Vis Sci. 1998; 39: 989–995, [PUBMED], [INFOTRIEVE], [CSA]
- Bora N S, Gobleman C L, Atkinson J P, Pepose J S, Kaplan H J. Differential expression of the complement regulatory proteins in the human eye. Invest Ophthalmol Vis Sci. 1993; 34: 3579–3584, [PUBMED], [INFOTRIEVE], [CSA]
- Goslings W R, Blom D J, de Waard-Siebinga I, van Beelen E, Claas F H, Jager M J, Gorter A. Membrane-bound regulators of complement activation in uveal melanomas. CD46, CD55, and CD59 in uveal melanomas. Invest Ophthalmol Vis Sci. 1996; 37: 1884–1891, [PUBMED], [INFOTRIEVE], [CSA]
- Streilein J W. Ocular immune privilege: therapeutic opportunities from an experiment of nature. Nat Rev Immunol. 2003; 3: 879–889, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Niederkorn J Y. Immune privilege in the anterior chamber of the eye. Crit Rev Immunol. 2002; 22: 13–46, [PUBMED], [INFOTRIEVE], [CSA]
- Niederkorn J Y. Immunology of uveal melanoma: immunosuppressive factors and the basis for immunotherapy. Ocular oncology, D M Albert, A Polans. Marcel Dekker, Inc., New York 2003; 255–268
- Niederkorn J Y. Immunopathogenesis of intraocular tumors. Prog Retinal Eye Res. 1995; 14: 505–526, [CROSSREF]
- Niederkorn J Y. Immunoregulation of intraocular tumours. Eye. 1997; 11: 249–254, [PUBMED], [INFOTRIEVE]
- Taylor A W. Ocular immunosuppressive microenvironment. Chem Immunol. 1999; 73: 72–89, [PUBMED], [INFOTRIEVE], [CSA]
- Griffith T S, Brunner T, Fletcher S M, Green D R, Ferguson T A. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science. 1995; 270: 1189–1192, [PUBMED], [INFOTRIEVE]
- Repp A CME, Mayhew E S, Howard K, Alizadeh H, Niederkorn J Y. Role of Fas ligand in uveal melanoma-induced liver damage. Graefes Arch Clin Exp Ophthalmol. 2001; 239: 752–758, [PUBMED], [INFOTRIEVE], [CSA]
- Osterlind A. Trends in incidence of ocular malignant melanoma in Denmark 1943–1982. Int J Cancer 1987; 40: 161–164
- Niederkorn J Y. The immunopathology of intraocular tumour rejection. Eye. 1991; 5: 186–192, [PUBMED], [INFOTRIEVE]
- Knisely T L, Luckenbach M W, Fischer B J, Niederkorn J Y. Destructive and nondestructive patterns of immune rejection of syngeneic intraocular tumors. J Immunol. 1987; 138: 4515–4523, [PUBMED], [INFOTRIEVE]
- Knisely T L, Niederkorn J Y. Emergence of a dominant cytotoxic T lymphocyte antitumor effector from tumor-infiltrating cells in the anterior chamber of the eye. Cancer Immunol Immunother. 1990; 30: 323–330, [PUBMED], [INFOTRIEVE]
- Ma D, Alizadeh H, Comerford S A, Gething M J, Sambrook J F, Anand R, Niederkorn J Y. Rejection of intraocular tumors from transgenic mice by tumor-infiltrating lymphocytes. Curr Eye Res. 1994; 13: 361–369, [PUBMED], [INFOTRIEVE]
- Schurmans L R, den Boer A T, Diehl L, van der Voort E I, Kast W M, Melief C J, Toes R E, Jager M J. Successful immunotherapy of an intraocular tumor in mice. Cancer Res. 1999; 59: 5250–5254, [PUBMED], [INFOTRIEVE]
- Wang S, Boonman Z F, Li H C, He Y, Jager M J, Toes R E, Niederkorn J Y. Role of TRAIL and IFN-gamma in CD4+ T cell-dependent tumor rejection in the anterior chamber of the eye. J Immunol. 2003; 171: 2789–2796, [PUBMED], [INFOTRIEVE]
- Lee H O, Herndon J M, Barreiro R, Griffith T S, Ferguson T A. TRAIL: a mechanism of tumor surveillance in an immune privileged site. J Immunol. 2002; 169: 4739–4744, [PUBMED], [INFOTRIEVE]
- Schurmans L R, Diehl L, den Boer A T, Sutmuller R P, Boonman Z F, Medema J P, van der Voort E I, Laman J, Melief C J, Jager M J, Toes R E. Rejection of intraocular tumors by CD4(+) T cells without induction of phthisis. J Immunol. 2001; 167: 5832–5837, [PUBMED], [INFOTRIEVE]
- Head J R, Billingham R E. Immunologically privileged sites in transplantation immunology and oncology. Perspect Biol Med. 1985; 29: 115–131, [PUBMED], [INFOTRIEVE], [CSA]
- Clark W H, JrElder D E, Guerry D T, Braitman L E, Trock B J, Schultz D, Synnestvedt M, Halpern A C. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst. 1989; 81: 1893–1904, [PUBMED], [INFOTRIEVE]
- Whelchel J C, Farah S E, McLean I W, Burnier M N. Immunohistochemistry of infiltrating lymphocytes in uveal malignant melanoma. Invest Ophthalmol Vis Sci. 1993; 34: 2603–2606, [PUBMED], [INFOTRIEVE]
- De l a, Cruz P O, Jr, Specht C S, McLean I W. Lymphocytic infiltration in uveal malignant melanoma. Cancer. 1990; 65: 112–115
- Makitie T, Summanen P, Tarkkanen A, Kivela T. Tumor-infiltrating macrophages (CD68(+) cells) and prognosis in malignant uveal melanoma. Invest Ophthalmol Vis Sci. 2001; 42: 1414–1421, [PUBMED], [INFOTRIEVE], [CSA]
- Prehn R T. Perspectives on oncogenesis: does immunity stimulate or inhibit neoplasia?. J Reticuloendothel Soc. 1971; 10: 1–16, [PUBMED], [INFOTRIEVE]